Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Denovo Starts Global Phase II Trial of Precision Medicine for Resistant Depression

publication date: Jul 29, 2022

Denovo Biopharma, a Hangzhou-San Diego precision medicine company, has started a global biomarker-guided Phase IIb clinical trial of its therapy for treatment resistant depression. DB104 (liafensine) is a first-in-class triple reuptake inhibitor targeting transporters for dopamine, serotonin and norepinephrine. Using its machine learning technology, the company discovered a novel genetic biomarker for DB104 efficacy. Denovo “rescues” drugs that did not meet their efficacy goals by finding a biomarker that defines a sub-population of patients in which the candidate is effective. Its DGM4 biomarker may be the first genetic biomarker-guided therapy for a mental health disorder. More details....<

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022